N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells
Autor: | Olivier Pradier, Daniel Pipeleers, Olivier Vosters, Zhidong Ling, Michel Goldman, Valérie Verhasselt, Claire Beuneu |
---|---|
Přispěvatelé: | Pathologic Biochemistry and Physiology |
Rok vydání: | 2006 |
Předmět: |
Adult
Male medicine.medical_specialty Cell Survival Endocrinology Diabetes and Metabolism medicine.medical_treatment Cell Biology Pharmacology Thromboplastin Islets of Langerhans Tissue factor Internal medicine Internal Medicine medicine Humans Platelet Blood Coagulation Islet cell transplantation geography geography.geographical_feature_category diabetes Middle Aged Islet Tissue Donors Acetylcysteine Transplantation Endocrinology medicine.anatomical_structure Female Beta cell |
Zdroj: | Vrije Universiteit Brussel |
ISSN: | 1432-0428 0012-186X |
Popis: | AIMS/HYPOTHESIS: The early loss of beta cells after islet cell transplantation has been attributed in part to blood coagulation at the implant site. Tissue factor expressed by beta cells and contaminating duct cells is considered to activate this process. Here, we investigated the ability of N-acetyl-L: -cysteine to suppress the in vitro procoagulant activity of duct cells and human islet cell preparations. MATERIALS AND METHODS: The effects of Nacystelyn, a salt derivative of N-acetyl-L: -cysteine, were first assessed on procoagulant activity induced in human plasma by recombinant tissue factor, human primary duct cells or human islet cell preparations. The influence of Nacystelyn on clot formation, platelet counts and D: -dimers were measured in a whole blood tubing loop model. Human beta cell viability and insulin synthesis after Nacystelyn treatment were assessed to exclude cytotoxicity of Nacystelyn. RESULTS: Nacystelyn efficiently inhibited the procoagulant activity of human recombinant tissue factor, primary duct cells and human islet cell preparations at clinically relevant concentrations without cellular toxicity. CONCLUSIONS/INTERPRETATION: Nacystelyn is a pharmaceutical candidate to reduce early beta cell loss related to tissue factor-dependent coagulation after islet transplantation. |
Databáze: | OpenAIRE |
Externí odkaz: |